Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Nagatomo, Yuji ^a   Meguro, Tomomi ^b   Ito, Hiroyuki ^a   Koide, Kimi ^a   Anzai, Toshihisa ^a   Fukuda, Keiichi ^a   Ogawa, Satoshi ^a   Yoshikawa, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; CORTICOSTERONE; DNA NUCLEOTIDYLEXOTRANSFERASE; EPLERENONE; GLUTATHIONE PEROXIDASE 1; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; PHOSPHOLAMBAN; PROTEIN BCL 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; MALE; MICE; MICE, KNOCKOUT; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84899742749     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093145     Document Type: Article

References (50)

1. Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34: 29-34.
2. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, et al. (2000) Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35: 1628-1637. (Pubitemid 30307510)
3. Matsue Y, SuzukiM, Nakamura R, Abe M, Ono M, et al. (2011) Prevalence and prognostic implications of pre-diabetic state in patients with heart failure. Circ J 75: 2833-2839.
4. Tsutsui H, Matsushima S, Kinugawa S, Ide T, Inoue N, et al. (2007) Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res 30: 439-449. (Pubitemid 46958894)
5. Joffe, II, Travers KE, Perreault-Micale CL, Hampton T, Katz SE, et al. (1999) Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with doppler echocardiography and contribution of the nitric oxide pathway. J Am Coll Cardiol 34: 2111-2119. (Pubitemid 30002673)
6. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE (2002) Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 98: 33-39. (Pubitemid 35375651)
7. Choi KM, Zhong Y, Hoit BD, Grupp IL, Hahn H, et al. (2002) Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in type 1 diabetic rats. Am J Physiol Heart Circ Physiol 283: H1398-1408.
8. Guo Z, Xia Z, Jiang J, McNeill JH (2007) Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. Am J Physiol Heart Circ Physiol 292: H1728-1736. (Pubitemid 46572395)
9. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, et al. (2001) IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 50: 1414-1424. (Pubitemid 32500175)
10. Matsushima S, Kinugawa S, Ide T, Matsusaka H, Inoue N, et al. (2006) Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 291: H2237-2245. (Pubitemid 44794216)
11. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, et al. (2002) Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106: 246-253. (Pubitemid 34761307)
12. Otani H, Otsuka F, Inagaki K, Suzuki J, Miyoshi T, et al. (2008) Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology 149: 2816-2825. (Pubitemid 351724501)
13. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91: 457-465. (Pubitemid 12203819)
14. Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, et al. (2002) Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40: 28-33. (Pubitemid 34755975)
15. Noda K, Kobara M, Hamada J, Yoshifuji Y, Shiraishi T, et al. (2012) Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts. J Cardiovasc Pharmacol 60: 140-149.
16. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717. (Pubitemid 29407370)
17. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321. (Pubitemid 36384098)
18. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, et al. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11-21.
19. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, et al. (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. Jama 309: 781-791.
20. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, et al. (1995) Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 270: 18719-18722.
21. Kanki H, Fukuda K, Okushi K, Ibata I, Toyama Y, et al. (1999) Comparison of nerve growth factor mRNA expression in cardiac and skeletal muscle in streptozotocin-induced diabetic mice. Life Sci 65: 2305-2313. (Pubitemid 29531033)
22. Katada J, Meguro T, Saito H, Ohashi A, Anzai T, et al. (2005) Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 111: 2157-2164. (Pubitemid 40632429)
23. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, et al. (1999) Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 84: 735-740. (Pubitemid 29157342)
24. Yamashita K, Okuyama M, Nakagawa R, Honma S, Satoh F, et al. (2008) Development of sensitive derivatization method for aldosterone in liquid chromatography-electrospray ionization tandem mass spectrometry of corticosteroids. J Chromatogr A 1200: 114-121.
25. Kaneko H, Anzai T, Horiuchi K, Morimoto K, Anzai A, et al. (2011) Tumor necrosis factor-alpha converting enzyme inactivation ameliorates high-fat diet-induced insulin resistance and altered energy homeostasis. Circ J 75: 2482-2490.
26. Mano Y, Anzai T, Kaneko H, Nagatomo Y, Nagai T, et al. (2011) Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. Circ J 75: 1717-1727.
27. Baba A, Yoshikawa T, Iwata M, Anzai T, Nakamura I, et al. (2006) Antigen-specific effects of autoantibodies against sarcolemmal Na-K-ATPase pump in immunized cardiomyopathic rabbits. Int J Cardiol 112: 15-20. (Pubitemid 44262405)
28. Qin F, Simeone M, Patel R (2007) Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free Radic Biol Med 43: 271-281. (Pubitemid 46977168)
29. Yang G, Meguro T, Hong C, Asai K, Takagi G, et al. (2001) Cyclosporine reduces left ventricular mass with chronic aortic banding in mice, which could be due to apoptosis and fibrosis. J Mol Cell Cardiol 33: 1505-1514. (Pubitemid 32681668)
30. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, et al. (2003) Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41: 2164-2171. (Pubitemid 36724261)
31. Sechi LA, Griffin CA, Schambelan M (1994) The cardiac renin-angiotensin system in STZ-induced diabetes. Diabetes 43: 1180-1184. (Pubitemid 24361181)
32. Al-Shafei AI, Wise RG, Gresham GA, Carpenter TA, Hall LD, et al. (2002) Magnetic resonance imaging analysis of cardiac cycle events in diabetic rats: the effect of angiotensin-converting enzyme inhibition. J Physiol 538: 555-572. (Pubitemid 35175380)
33. Delcayre C, Swynghedauw B (2002) Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 34: 1577-1584. (Pubitemid 36001997)
34. Solomon SD, Pfeffer MA (2003) Aldosterone antagonism and myocardial infarction: from animals to man and back. J Am Coll Cardiol 42: 1674-1676. (Pubitemid 37378452)
35. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, et al. (2001) Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem 276: 38911-38920.
36. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, et al. (2005) Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111: 3025-3033. (Pubitemid 40847778)
37. Nagata K, Obata K, Xu J, Ichihara S, Noda A, et al. (2006) Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in lowaldosterone hypertensive rats. Hypertension 47: 656-664. (Pubitemid 43740235)
38. Takeda M, Tatsumi T, Matsunaga S, Hayashi H, Kimata M, et al. (2007) Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res 30: 427-437. (Pubitemid 46958893)
39. Castren M, Trapp T, Berninger B, Castren E, Holsboer F (1995) Transcriptional induction of rat mineralocorticoid receptor gene in neurones by corticosteroids. J Mol Endocrinol 14: 285-293.
40. Sato A, Saruta T (2001) Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29: 13-21. (Pubitemid 32236891)
41. Ogawa S, Takeuchi K, Mori T, Nako K, Ito S (2006) Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol 33: 477-479.
42. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, et al. (2001) Aldosterone production is activated in failing ventricle in humans. Circulation 103: 72-77. (Pubitemid 32050438)
43. Wang H, Shimosawa T, Matsui H, Kaneko T, Ogura S, et al. (2008) Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens 26: 1453-1462.
44. Rossier MF, Lenglet S, Vetterli L, Python M, Maturana A (2008) Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes. Hypertension 52: 721-728.
45. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, et al. (2003) Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 93: 69-76. (Pubitemid 36859043)
46. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, et al. (2002) Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8: 473-479. (Pubitemid 34546749)
47. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, et al. (2002) Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51: 1166-1171. (Pubitemid 34438364)
48. Zhang L, Cannell MB, Phillips AR, Cooper GJ, Ward ML (2008) Altered calcium homeostasis does not explain the contractile deficit of diabetic cardiomyopathy. Diabetes 57: 2158-2166.
49. O'Keefe JH, Abuissa H, Pitt B (2008) Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 10: 492-497. (Pubitemid 351639092)
50. Gorcsan J 3rd, Strum DP, Mandarino WA, Gulati VK, Pinsky MR (1997) Quantitative assessment of alterations in regional left ventricular contractility with color-coded tissue Doppler echocardiography. Comparison with sonomicrometry and pressure-volume relations. Circulation 95: 2423-2433. (Pubitemid 27224738)